Nanjing Rongjiekang RC1416 dual antibody has obtained 2 clinical trial licenses again

Recently, Nanjing RegeneCore Biotechnology Co., Ltd.'s RC1416 project has consecutively obtained Investigational New Drug (IND) approvals from the National Medical Products Administration's Center for Drug Evaluation (CDE) for indications of atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD). The expansion of these indications has further diversified the clinical application scenarios of RC1416 injection, providing better treatment options for more patients..

融捷集团：竞逐新赛道，勇攀生命科技高峰

近日，南京融捷康生物科技有限公司发布的一则招募中重度哮喘患者的消息引人关注。原来，由融捷康自研的国内首个自免双特异性纳米抗体药物——RC1416注射液，正在全国数十家知名医院开展临床研究。这款双抗药品在药效、安全性和成药性等多重指标上具有较好的优势，未来有望成为中重度哮喘患者的福音。

Recruitment of Patients with Moderate to Severe Asthma

RC1416 injection, developed by Nanjing RegeneCore Biotech Co.,Ltd, is currently undergoing a Phase Ib clinical study to "evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary effectiveness of RC1416 injection in patients with moderate to severe asthma." The lead institution for this study is the China-Japan Friendship Hospital in Beijing, and it is simultaneously being conducted at dozens of renowned hospitals across the country.